• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHEN Jiajia, BEI Yuncheng, ZHANG Dongmei, SHEN Pingping. Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446[J]. Journal of China Pharmaceutical University, 2017, 48(2): 201-207. DOI: 10.11665/j.issn.1000-5048.20170211
Citation: CHEN Jiajia, BEI Yuncheng, ZHANG Dongmei, SHEN Pingping. Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446[J]. Journal of China Pharmaceutical University, 2017, 48(2): 201-207. DOI: 10.11665/j.issn.1000-5048.20170211

Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446

More Information
  • This study was to investigate the inhibitory effects of artemether in combination with etoposide on the proliferation and invasion ability of human small cell lung cancer cell line H446. H446 cells were treated with different concentrations of artemether or etoposide alone or their combination. The inhibitory effects on proliferation were detected by MTT assay, while cell cycle and apoptosis of H446 cells in each group were analyzed by flow cytometry using PI and Annexin V/PI-staining, respectively. The invasion capability of H446 cells in different groups was tested with matrigel-coated transwell. The results implicated that artemether or etoposide or their combination does inhibit proliferation of H446 cells dose-dependently. Artemether alone had little effect on the apoptosis of H446 cells while its combination with etoposide resulted in significantly apoptosis of H446 cells comparing with other groups(P< 0. 05). Etoposide blocked H446 progression markedly by arresting cell cycle in G2 phase with percentage of cells in G1 phase decreasing significantly while artemether alone or in combination with etoposide had little synergetic effect on cell cycle. Artemether or etoposite alone or their combination could dramatically inhibit the invasion ability of H446 cells.
  • [1]
    Byers LA,Rudin CM.Small cell lung cancer:where do we go from here[J]?Cancer,2015,121(5):664-672.
    [2]
    Asai N,Ohkuni Y,Kaneko N,et al.Relapsed small cell lung cancer:treatment options and latest developments[J].Ther Adv Med Oncol,2014,6(2):69-82.
    [3]
    Chaturvedi D,Goswami A,Saikia PP,et al.Artemisinin and its derivatives:a novel class of anti-malarial and anti-cancer agents[J].Chem Soc Rev,2010,39(2):435-454.
    [4]
    Chen T,Li M,Zhang R,et al.Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy[J].J Cell Mol Med,2009,13(7):1358-1370.
    [5]
    Gong Y,Gallis BM,Goodlett DR,et al.Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines[J].Anticancer Res,2013,33(1):123-132.
    [6]
    Lai HC,Singh NP,Sasaki T.Development of artemisinin compounds for cancer treatment[J].Invest New Drugs,2013,31(1):230-46.
    [7]
    Lu JJ, Chen SM, Zhang XW, et al. The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells[J].Invest New Drugs,2011,29(6):1276-1283.
    [8]
    Das AK.Anticancer effect of antimalarial artemisinin compounds[J].Ann Med Health Sci Res,2015,5(2):93-102.
    [9]
    Guo T,Li HY,Yin XZ,et al. Mechanism of cyclodextrin inclusion of artemisinins in vacuum[J].J China Pharm Univ(中国药科大学学报),2010,41(6):513-519.
    [10]
    Simos D,Sajjady G,Sergi M,et al.Third-line chemotherapy in small-cell lung cancer:an international analysis[J].Clin Lung Cancer,2014,15(2):110-118.
    [11]
    Ho WE,Peh HY,Chan TK,et al.Artemisinins:pharmacological actions beyond anti-malarial[J].Pharmacol Ther,2014,142(1):126-139.
  • Related Articles

    [1]TANG qian, CHEN Roufen, SHEN Zheyuan, CHI Xinglong, CHE Jinxin, DONG Xiaowu. Research progress of artificial intelligence-based small molecule generation models in drug discovery[J]. Journal of China Pharmaceutical University, 2024, 55(3): 295-305. DOI: 10.11665/j.issn.1000-5048.2024031501
    [2]Gao Zhonghao. 新型药物递送系统技术在药物研发中的应用和展望[J]. Journal of China Pharmaceutical University, 2023, 54(1): 1-4. DOI: 10.11665/j.issn.1000-5048.2023030303
    [3]FU Mingyu, ZHU Yiyang, WU Chunyong, HOU Fengzhen, GUAN Yuan. Prediction of plasma protein binding rate based on machine learning[J]. Journal of China Pharmaceutical University, 2021, 52(6): 699-706. DOI: 10.11665/j.issn.1000-5048.20210607
    [4]MEI Jiahao, HONG Ze, WANG Chen. Advances of drugs in targeting cGAS-STING signaling pathway[J]. Journal of China Pharmaceutical University, 2020, 51(3): 249-259. DOI: 10.11665/j.issn.1000-5048.20200301
    [5]ZHANG Jing. Analysis on research and development of global cardiovascular drugs in the past 6 years[J]. Journal of China Pharmaceutical University, 2018, 49(6): 760-765. DOI: 10.11665/j.issn.1000-5048.20180619
    [6]WANG Chen, ZHANG Zhewen, LI Yingchun, ZHANG Xiquan, ZHAO Wei. Advances of the effects of antibody heterogeneity on the function and metabolism of monoclonal antibody drugs[J]. Journal of China Pharmaceutical University, 2017, 48(5): 614-621. DOI: 10.11665/j.issn.1000-5048.20170518
    [7]Yeast for New Drug Research[J]. Journal of China Pharmaceutical University, 2004, (6): 109-113.
    [8]Gene Knockout Model and New Drug Target Discovery[J]. Journal of China Pharmaceutical University, 2004, (1): 3-8.
    [9]Application of Genechip Technology in Drug Discovery and Development[J]. Journal of China Pharmaceutical University, 2001, (2): 1-6.
    [10]Advances and Prospects of Drug Discovery and Development Zhang Yihua, Peng Sixun, Hua Weiyi[J]. Journal of China Pharmaceutical University, 1999, (2): 75-80.

Catalog

    Article views (780) PDF downloads (1421) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return